Fig. 4From: A composite biomarker of neutrophil-lymphocyte ratio and hemoglobin level correlates with clinical response to PD-1 and PD-L1 inhibitors in advanced non-small cell lung cancersAssociation of a composite biomarker of NLR and hemoglobin and OS at baseline (a, b), 2–8 weeks (c, d), change of NLR from baseline to 2–8 weeks (e, f)Back to article page